GO
Loading...

Enter multiple symbols separated by commas

Search results for "MRK"

REFINE RESULTS

SEARCH RESULTS

About 57 results. Sort By: Date | Relevance
BMY hit on disappointing drug trial  

Dissecting the day's major business news, with the Fast Money traders. Bristol-Myers gets hit hard on disappointing results from a lung cancer drug.
Source: CNBC.com
UPDATE 1-Bristol's Opdivo cuts risk of lung cancer death for some

Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...
Source: Reuters | By: Deena Beasley
Stocks close lower but post gains for May; data, Greece weigh

U.S. stocks closed lower on the last trading day of the month, as investors digested data and remained cautious on continued concerns about Greece.
Source: CNBC.com | By: Evelyn Cheng
These biotechs may surge on drug news: Expert

Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
Source: CNBC.com | By: Jacob Pramuk
Here's why Puma, Clovis shares are poised to move

It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, there are a few stocks to watch, including Puma Biotechnology and Clovis Oncology.
Source: CNBC.com | By: Meg Tirrell
New class of drugs shows promise for cancer fight

A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Source: The New York Times | By: Andrew Pollack
Bristol's Opdivo reduces risk of death from common lung cancer

Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...
Source: Reuters | By: Deena Beasley
ASCO targets war on cancer  

CNBC's Meg Tirrell, provides a preview of this weekend's meeting of the American Society of Clinical Oncology and which big pharma companies investors need to watch come Monday.
Source: CNBC.com
Top trades before the closing bell

The "Halftime Report" traders give their top trades for the second half of the trading day.
Source: CNBC.com | By: Bree Kelly
6 trades on big day for chip makers

Intel, Qualcomm and Broadcom all saw big gains on Wednesday, and "Fast Money" traders discussed which names have more room to run.
Source: CNBC.com | By: Jacob Pramuk